Origami Therapeutics

Origami Therapeutics is an early-stage biotech pioneering a novel approach to treating disease by developing small molecules that target and degrade disease-causing proteins. The company is leveraging protein degradation technology, aiming for selectivity and broad tissue distribution, with an initial focus on major neurodegenerative conditions like Alzheimer's, Parkinson's, and Huntington's diseases. As a private, preclinical-stage company, it is positioned in the competitive but high-potential field of targeted protein degradation, seeking to address significant unmet medical needs.

Small molecule-based targeted protein degradation and correction platform designed to selectively remove disease-causing proteins while sparing normal ones, with a focus on broad tissue distribution.

Origami operates in the highly competitive fields of targeted protein degradation and neurodegenerative disease drug development. It faces competition from dedicated protein degradation companies (e.g., Arvinas, Kymera, Nurix) and large pharmaceutical firms with significant neuroscience divisions, all pursuing similar targets and mechanisms for conditions like Alzheimer's and Parkinson's.